Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

The FDA has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) against ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences’ twice-yearly injection to prevent HIV - a move the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who ...

Gilead Sciences, Inc., a biopharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) ...

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

The FDA has approved Gilead Sciences' lenacapavir, sold under the name Yeztugo, as a twice-yearly injection for preventing ...

The U.S. FDA approved Gilead Sciences' lenacapavir, under the brand name Yeztugo, for HIV prevention. This twice-yearly ...

Gilead has plans for a rapid launch in the United States as well as a wider rollout of the drug in collaboration with global ...